Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia.
Asian Pac J Allergy Immunol
;
1989 Dec; 7(2): 103-5
Article
in English
| IMSEAR
| ID: sea-36971
ABSTRACT
Four patients with chronic myelogenous leukemia and thrombocytosis and one patient with essential thrombocythemia were treated with purified recombinant human interferon alpha-2a (IFN-alpha 2a). Significant decline in platelet counts, from a mean ( +/- SE) of 1.396 +/- 0.265 x 10(6)/mm3 to a mean of 0.396 +/- 0.04 x 10(6)/mm3 (p less than 0.05), was observed in all patients. The platelet count remained normal for 15, 21 and 30 days after discontinuation of IFN-alpha 2a in 3 patients. In 2 patients the platelet count began to rise slowly two weeks after discontinuation of IFN-alpha 2a. Our preliminary observations suggest that purified recombinant human IFN-alpha 2a may effectively control progressive thrombocytosis in advanced chronic myelogenous leukemia and essential thrombocythemia.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Platelet Count
/
Thrombocytosis
/
Aged
/
Female
/
Humans
/
Male
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Interferon Type I
/
Adult
/
Interferon alpha-2
Language:
English
Journal:
Asian Pac J Allergy Immunol
Year:
1989
Type:
Article
Similar
MEDLINE
...
LILACS
LIS